Parts of a Theranostic Drug
Learn
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Office
Fax
402-991-8469
Luke Nordquist, MD, FACP
CEO
Tony Romero, MS, CCRC
Director of Research
Clinical Trial · NCT06494800
Overview
Assess the value of PET/CT in the diagnosis, staging, response evaluation, and relapse monitoring of lung cancer.
Sponsor
Phase
N/A
ClinicalTrials.gov
Drug / Compound
Help us improve your experience